Novel Diagnostics With Optical Coherence Tomography: Retinal Imaging

This study is currently recruiting participants.

Verified July 2011 by University of Pittsburgh

First Received on June 19, 2006. Last Updated on July 25, 2011 History of Changes

Sponsor:	University of Pittsburgh
Information provided by:	University of Pittsburgh
ClinicalTrials.gov Identifier:	NCT00343746

Purpose

The purpose of this research is to evaluate optical coherence tomography (OCT) and FDA approved device used to image diseases of the eye. The ultra-high resolution OCT is a non-significant risk device used in this study. Optical Coherence Tomography may be useful for early diagnosis and monitoring of different types of eye diseases.

Condition	Phase
Macular Degeneration Glaucoma Diabetic Retinopathy.	Phase I

Study Type:	Observational
Official Title:	Novel Diagnostics With Optical Coherence Tomography: Retinal Imaging

Resource links provided by NLM:

Genetics Home Reference related topics: 6q24-related transient neonatal diabetes mellitus age-related macular degeneration early-onset glaucoma X-linked juvenile retinoschisis

MedlinePlus related topics: Diabetic Eye Problems Eye Diseases Glaucoma Macular Degeneration Retinal Disorders

U.S. FDA Resources

Further study details as provided by University of Pittsburgh:

Estimated Enrollment:	1500
Study Start Date:	October 2005
Estimated Study Completion Date:	October 2012
Estimated Primary Completion Date:	October 2012 (Final data collection date for primary outcome measure)

Detailed Description:

The purpose of this research is to evaluate optical coherence tomography (OCT) and FDA approved device used to image diseases of the eye. The ultra-high resolution OCT is a non-significant risk device used in this study. OCT may be useful for early diagnosis and monitoring of different types of eye diseases.

Eligibility

Ages Eligible for Study:	18 Years to 90 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	Yes
Sampling Method:	Non-Probability Sample

Study Population

Subjects can be 18 to 90 years of age. They can be male or female. Recruiting for normal and diseased subjects.

Criteria

Inclusion Criteria:

Subjects with healthy eyes, macular degeneration, glaucoma and other various eye diseases. Also must be able to fixate on target.

Exclusion Criteria:

If the fundus is not visible if the media is opaque and if they are unwilling to participate.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00343746

Contacts

Contact: Kristy A Truman	412-383-8778	trumank@upmc.edu
Contact: Melessa Slaay, COA	412-383-9884	salaymd@upmc.edu

Locations

United States, Pennsylvania
University of Pittsburgh UPMC Eye Center	Recruiting
Pittsburgh, Pennsylvania, United States, 15213
Principal Investigator: Joel S Schuman, MD

Sponsors and Collaborators

University of Pittsburgh

Investigators

Study Chair:	Joel S Schuman, MD	University of Pittsburgh
Principal Investigator:	Gadi Wollstein, MD	University of Pittsburgh
Study Director:	Hiroshi Ishikawa, MD	University of Pittsburgh

More Information

No publications provided

Responsible Party:	Gadi Wollstein M.D. / Melessa Salay, UPMC Eye Center
ClinicalTrials.gov Identifier:	NCT00343746 History of Changes
Other Study ID Numbers:	0309021, Ro1 EY 11289-15
Study First Received:	June 19, 2006
Last Updated:	July 25, 2011
Health Authority:	United States: Institutional Review Board

Keywords provided by University of Pittsburgh:

macular degeneration
glaucoma
diabetic retinopathy
retinopathy, eye diseases

Additional relevant MeSH terms:

Diabetic Retinopathy
Glaucoma
Macular Degeneration
Retinal Diseases
Eye Diseases
Diabetic Angiopathies
Vascular Diseases

Cardiovascular Diseases
Diabetes Complications
Diabetes Mellitus
Endocrine System Diseases
Ocular Hypertension
Retinal Degeneration

ClinicalTrials.gov processed this record on February 09, 2012